Mepolizumab Improves Symptoms in Chronic Rhinosinusitis With Nasal Polyps
Mepolizumab reduces disease symptoms in patients with chronic rhinosinusitis with nasal polyps, according to the results of a randomized, double-blind, multicenter study.
Mepolizumab reduces disease symptoms in patients with chronic rhinosinusitis with nasal polyps, according to the results of a randomized, double-blind, multicenter study.
Berotralstat may reduce the use of on-demand medications in patients with hereditary angioedema (HAE) who were previously treated with prophylactic therapies.
In patients with moderate to severe chronic rhinosinusitis with nasal polyposis, treatment with an Exhalation Delivery System With Fluticasone (EDS-FLU) is associated with improved sleep scores.
Active eosinophilic esophagitis appears to be associated with lower lung function and increased asthma severity in children with comorbid asthma.
Dupilumab significantly reduced severe asthma exacerbations and improved prebronchodilator FEV1 in patients with baseline FeNO greater than or equal to 25 ppb with/without substantial FeNO reduction.
In patients with COPD, treatment with single-inhaler fluticasone furoate/umeclidinium/vilanterol resulted in more health status improvements and greater lung function benefit compared with multiple-inhaler triple therapy.
BAY 1817080, a potent selective P2X3 receptor antagonist, may have utility as a new treatment for refractory chronic cough.
Pitolisant may be used as an add-on therapy to continuous positive airway pressure in patients with obstructive sleep apnea suffering from residual diurnal somnolence.
CSJ117, formulated as an engineered powder in hard capsules for delivery to the lungs via dry powder inhaler, may be the first inhaled anti-thymic stromal lymphopoietin treatment for adults with mild asthma.